References
- 1. PINCOCK S. Nobel Prize winners Robin Warren and Barry Marshall. Lancet. 2005; 366(9495):1429.
- 2. HOOI JKY., LAI WY., Ng WK., SUEN MMY., UNDERWOOD FE., TANYINGOH D., et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017; 153(2):420–9.
- 3. PARKINSON AJ., GOLD BD., BULKOW L., WAINWRIGHT RB., SWAMINATHAN B., KHANNA B., et al. High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol. 2000; 7(6):885–8.
- 4. EVERHART JE., KRUSZON-MORAN D., PEREZ-PEREZ GI., TRALKA TS., MCQUILAN G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis. 2000; 181(4):1359–63.
- 5. CARDENAL VM., MULLA ZD., ORTIZ M., GRAHAM DY. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol. 2006; 163(2):127–34.
- 6. SCHWARZ S., MORELLI G., KUSECEK B., MANICA A., BALLOUX F., OWEN RJ., et al. Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog. 2008; 4(10):e1000180.
- 7. FORD AC., FORMAN D., BAILEY AG., GOODMAN KJ., AXON AT., MOAYYEDI P. Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. Int J Epidemiol. 2007; 36(6):1327–33.
- 8. WEYERMANN M., ROTHENBACHER D., BRENNER H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol. 2009; 104(1):182–9.
- 9. JIANG J., CHEN Y., SHI J., SONG C., ZHANG J., WANG K. Population attributable burden of Helicobacter pylori-related gastric cancer, coronary heart disease, and ischemic stroke in China. Eur J Clin Microbiol Infect Dis. 2017; 36(2):199–212.
- 10. GONI E., FRANCESCHI F. Helicobacter pylori and extragastric diseases. Helicobacter. 2016; 21 Suppl 1:45–8.
- 11. LIU J., WANG F., SHI S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants. Helicobacter. 2015; 20(3):176–83.
- 12. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994; 61:1–241.
- 13. KOSUNEN TU., PUKKALA E., SARNA S., SEPPALA K., AROMAA A., KNEKT P., et al. Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study. Int J Cancer. 2011; 128(2):433–9.
- 14. CHEY WD., LEONITIADIS GI., HOWDEN CW., MOSS SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 112(2):212–39.
- 15. NAKAMURA S., SUGIYAMA T., MATSUMOTO T., IIJIMA K., ONO S., TAJIKA M., et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012; 61(4):507–13.
- 16. YOON SB., PARK JM., LIM CH., CHO YK., CHOI MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014; 19(4):243–8.
- 17. RAGHUNATH AS., HUNGIN AP., WOOFF D., CHILDS S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther. 2004; 20(7):733–44.
- 18. HOWDEN CW., HUNT RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998; 93(12):2330–8.
- 19. GRAHAM DY., MIFTAHUSSURUR M. Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: A mini review. J Adv Res. 2018; 13:51–7.
- 20. CHEY WD., WONG BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102(8):1808–25.
- 21. TREVISANI L., SARTORI S., GALVANI F., ROSSI MR., RUINA M., CHIAMENTI C., et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Am J Gastroenterol. 1999; 94(7):1830–3.
- 22. VAIRA D., MALFERHEINER P., MEGRAUD F., AXON AT., DELTENRE M., HIRSCHL AM., et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet. 1999; 354(9172):30–3.
- 23. MALFERHEINER P., MEGRAUD F., O’MORAIN CA., ATHERTON J., AXON AT., BAZZOLI F., et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut. 2012; 61(5):646–64.
- 24. MALFERHEINER P., MEGRAUD F., MORAIN CA., GISBERT JP., KUIPERS EJ., AXON AT., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1):6.
- 25. YANEZ P., LA GARZA AM., PEREZ-PEREZ G., CABRERA L., MUNOZ O., TORRES J. Comparison of invasive and noninvasive methods for the diagnosis and evaluation of eradication of Helicobacter pylori infection in children. Arch Med Res. 2000; 31(4):415–21.
- 26. BRANDI G., BIAVATI B., CALABRESE C., GRANATA M., NANNETTI A., MATTARELLI P., et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol. 2006; 101(8):1756–61.
- 27. WRIGHT CL., KELLY JK. The use of routine special stains for upper gastrointestinal biopsies. Am J Surg Pathol. 2006; 30(3):357–61.
- 28. GENTA RM., GRAHAM DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc. 1994; 40(3):342–5.
- 29. TAYLOR DE., GE Z., PURYCH D., LO T., HIRATSUKA K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother. 1997; 41(12):2621–8.
- 30. HIRSCHL AM., MAKRISTATHIS A. Methods to detect Helicobacter pylori: from culture to molecular biology. Helicobacter. 2007; 12 Suppl 2:6–11.
- 31. YUAN Y., FORD AC., KHAN KJ., GISBERT JP., FORMAN D., LEONTIADIS GI., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013; (12):Cd008337.
- 32. FALLONE CA., CHIBA N., VAN ZANTEN SV., FISCHBACH L., GISBERT JP., HUNT RH., et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016; 151(1):51–69.e14.
- 33. LI BZ., THREAPLETON DE., WANG JY., XU JM., YUAN JQ., ZHANG C., et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. Bmj. 2015; 351:h4052.
- 34. NISTA EC., CANDELLI M., CREMONINI F., CAZZATO IA., DI CAROA S., GABRIELLI M., et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003; 18(6):627–33.
- 35. BILARDI C., DULBECCO P., ZENTILIN P., REGLIONI S., IIRITANO E., PARODI A., et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004; 2(11):997–1002.
- 36. SAAD RJ., SCHOENFELD P., KIM HM., CHEY WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006; 101(3):488–96.
- 37. ERCIN CN., UYGUN A., TOROS AB., KANTARCIOGLU M., KILCILER G., POLAT Z., et al. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol. 2010; 21(1):12–6.
- 38. BASU PP., RAYAPUDI K., PACANA T., SHAH NJ., KRISHNASWAMY N., FLYNN M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011; 106(11):1970–5.
- 39. KALE-PRADHAN PB., MIHAESCU A., WILHELM SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy. 2015; 35(8):719–30.
- 40. GREENBERG ER., ANDERSON GL., MORGAN DR., TORRES J., CHEY WD., BRAVO LE., et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011; 378(9790):507–14.
- 41. MIEHLKE S., HHANSKY K., SCHNEIDER-BRACHERT W., KIRSCH C., MORGANER A., MADISCH A., et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006; 24(2):395–403.
- 42. LABENZ J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol. 2001; 15(3):413–31.
- 43. SHIOTA S., REDDY R., ALSARRAJ A., EL-SSERAG HB., GRAHAM DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015; 13(9):1616–24.
- 44. PERRI F., FESTA V., CLEMENTE R., VILLANI MR., QUITADAMO M., CARUSO N., et al. Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001; 96(1):58–62.
- 45. GISBERT JP., ABRAIRA V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol. 2006; 101(4):848–63.
- 46. GISBERT JP., ESTEBAN C., JIMENEZ I., MORENO-OTERO R. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter. 2007; 12(3):231–7.
- 47. MIEHLKE S., KIRSCH C., SCHNEIDER-BRACHERT W., HHAFERLAND C., NEUMEYER M., BASTLEIN E., et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003; 8(4):310–9.
- 48. CAO Z., CCHEN Q., ZHANG W., LIANG X., LIAO J., LIU W., et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015; 50(10):1185–90.
- 49. DONG SQ., SINGH TP., WEI X., YAO H., WANG HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter. 2017; 22(6):e12438.